MAPKAPK3
Sign in to save this workspaceUniProt Q16644 · PDB · AlphaFold · Substrate: Glycogen Synthase-derived peptide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dasatinib | 18.6% | 81.4% | 87.97 | 0.699 |
| 2 | Repotrectinib | 17.7% | 82.3% | 84.21 | 0.608 |
| 3 | Afatinib | 15.2% | 84.8% | 98.50 | 0.709 |
| 4 | Tivozanib | 14.9% | 85.1% | 92.42 | 0.673 |
| 5 | Bosutinib | 14.8% | 85.2% | 87.22 | 0.555 |
| 6 | Midostaurin | 14.4% | 85.6% | 78.64 | 0.500 |
| 7 | Regorafenib | 11.5% | 88.5% | 95.99 | 0.719 |
| 8 | Ruxolitinib | 11.4% | 88.6% | 98.25 | 0.592 |
| 9 | Umbralisib | 11.2% | 88.8% | 98.74 | 0.670 |
| 10 | Erlotinib | 10.7% | 89.3% | 99.75 | 0.695 |
| 11 | Gilteritinib | 10.5% | 89.5% | 88.97 | 0.506 |
| 12 | Nintedanib | 10.4% | 89.6% | 90.23 | 0.608 |
| 13 | Lapatinib | 10.0% | 90.0% | 99.25 | 0.616 |
| 14 | Axitinib | 9.9% | 90.1% | 93.23 | 0.688 |
| 15 | Brigatinib | 9.8% | 90.2% | 82.96 | 0.513 |
| 16 | Acalabrutinib | 9.7% | 90.3% | 99.50 | 0.670 |
| 17 | Entrectinib | 9.3% | 90.7% | 93.69 | 0.671 |
| 18 | Lazertinib | 8.9% | 91.1% | 97.47 | 0.674 |
| 19 | Defactinib | 8.9% | 91.1% | 92.68 | 0.450 |
| 20 | Leniolisib | 8.6% | 91.4% | 100.00 | 0.604 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.54
- Epithelial log2(TPM+1): 4.63
- Fold change: -0.09
- Status: No significant change
Selectivity landscape vs inhibition on MAPKAPK3
Each point is one of the 92 approved drugs; color = inhibition % on MAPKAPK3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…